HSBC analyst downgraded AstraZeneca's rating, noting that AstraZeneca trails GSK in stock performance.
1 report, 1 independent
Updated Jul 24
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
HSBC analyst downgraded AstraZeneca's rating, noting that AstraZeneca trails GSK in stock performance.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Companies like BAE Systems, GSK, AstraZeneca, and HSBC are benefiting from geopolitical tensions, market recoveries, and strong market conditions in Europe.Also in this story
- easyJet soared on the FTSE 250, while GSK losses contributed to the FTSE 100 decline, alongside a rise in Bank of Ireland shares.
- GSK and AstraZeneca are utilizing Manchester as a base for their talent pipeline development and early career scientist recruitment events.
- Market performance update on July 1, 2026, showing mixed results for companies including AstraZeneca, with some rallying and others facing deepening losses in their sugar business.
The entities involved
-
HSBC
British multinational bank
-
AstraZeneca
British-Swedish pharmaceutical company
-
GSK
British multinational pharmaceutical and biotechnology company
Related events
- Jefferies Financial Group provided analyst ratings for AstraZeneca stock on June 20, 2026.
- Shell overtook HSBC as the most valuable company, while AstraZeneca and Unilever are noted as global peers.
- HSBC downgraded Itau Unibanco stock rating on October 17, 2026.
- AstraZeneca listed shares on the New York Stock Exchange to attract investors.
- First Solar, HSBC, and Nasdaq are involved in a new development: the company listed on the stock exchange and received rating upgrades and downgrades.
Coverage
Newest first; wire copies grouped- yahoo.comAnalysis-AstraZeneca 'magic' faces rare test after trial failure, share slide